SCHEMBL14829554

SCHEMBL14829554

O=Cc1ccc2ncc(NCCO)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 1/20 0.60
POLB P06746 1/20 0.60
GAA P10253 1/20 0.60
PIK3CA P42336 3/20 0.38
MAP4K4 O95819 4/20 0.36
CLK4 Q9HAZ1 4/20 0.36
MINK1 Q8N4C8 3/20 0.36
TYK2 P29597 2/20 0.36
SRPK1 Q96SB4 1/20 0.36
MET P08581 1/20 0.36
JAK2 O60674 3/20 0.36
CLK2 P49760 3/20 0.36
DYRK1A Q13627 3/20 0.36
ROCK2 O75116 2/20 0.36
GSK3B P49841 2/20 0.36
RPS6KB1 P23443 1/20 0.36
ROCK1 Q13464 1/20 0.36
RHOA P61586 1/20 0.36
PDE10A Q9Y233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12199223 0.76 KDM4E (1.00) KDM4EALDH1A1POLBGAAMAP4K4
SCHEMBL3299277 0.76 ALDH1A1 (0.44) KDM4EALDH1A1POLBGAAMAP4K4
SCHEMBL14829606 0.73 MEN1 (0.39) KDM4EALDH1A1PIK3CARHOACYP1A2
SCHEMBL15652730 0.72 KDM4E (0.42) KDM4EALDH1A1POLBLMNA
SCHEMBL14829741 0.69 TGFBR1 (0.42) KDM4EALDH1A1POLBCDK1CDK5
SCHEMBL5909656 0.69 ALDH1A1 (0.47) KDM4EALDH1A1POLBGAADYRK1A
SCHEMBL16507518 0.69 CDK8 (0.47) KDM4EALDH1A1POLBGAAEGFR
SCHEMBL14829842 0.68 KDM4E (0.47) KDM4EALDH1A1POLBGAAPIK3CA
SCHEMBL14829742 0.68 KDM4E (0.47) KDM4EALDH1A1POLBGAAPIK3CA
SCHEMBL13365646 0.68 KDM4E (0.61) KDM4EALDH1A1POLBGAAMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013049701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2013-04-04 WO claimed
US-20170050938-A1 SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS NEUPHARMA, INC. 2017-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050938-A1 SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS BRAF, RAF1, ARAF KDM4E 1448/4885ALDH1A1 2511/4885POLB 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.